To cite this paper use one of the standards below:
A virtual screening conducted with nearly 4,000,000 compounds from lead-like and fragment-like subsets enabled the identification of a promising small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas’ disease.1 Subsequent comprehensive structure–based drug design and structure–activity relationship studies lead to the discovery of carbamoylimidazoles, as potent and reversible cruzain inhibitors. The three structural fragments of hit 1 were explored and 42 compounds were synthesized. The most potent carbamoylimidazole (45) exhibited high affinity with a Ki value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, compounds 1 and 45 reduced parasite burden in vivo and showed no toxicity at doses of 100 mg/kg. These carbamoylimidazoles are structurally attractive, easy to prepare and synthetically modify. These results further advances our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper